Advanced

Circulating biomarkers for prostate cancer

Steuber, Thomas; Helo, Pauliina and Lilja, Hans LU (2007) In World Journal of Urology 25(2). p.111-119
Abstract
Due to its significant applicability for early detection, risk prediction and follow-up evaluation, prostate specific antigen (PSA) has revolutionized our ability to treat prostate cancer patients. With the prevalent use of PSA for early detection during the last two decades, disease characteristics have been altered towards early detected, localized tumors with a high chance of cure following local therapy. This advantage faces the risk of overdetection and overtreatment. In addition, PSA lacks both, sensitivity and specificity to accurately detect patients at risk of prostate cancer. Therefore, novel biomarkers are urgently needed to improve identification of men at risk of having the disease and to predict the natural behaviour of the... (More)
Due to its significant applicability for early detection, risk prediction and follow-up evaluation, prostate specific antigen (PSA) has revolutionized our ability to treat prostate cancer patients. With the prevalent use of PSA for early detection during the last two decades, disease characteristics have been altered towards early detected, localized tumors with a high chance of cure following local therapy. This advantage faces the risk of overdetection and overtreatment. In addition, PSA lacks both, sensitivity and specificity to accurately detect patients at risk of prostate cancer. Therefore, novel biomarkers are urgently needed to improve identification of men at risk of having the disease and to predict the natural behaviour of the tumor. Recent advances in the evaluation of high-throughput technologies have led to the discovery of novel candidate markers for prostate cancer. This article will briefly discuss current PSA-based strategies and review several novel biomarkers for prostate cancer, detectable in blood. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
World Journal of Urology
volume
25
issue
2
pages
111 - 119
publisher
Springer
external identifiers
  • PMID:17345087
  • Scopus:34047134452
ISSN
1433-8726
DOI
10.1007/s00345-007-0160-0
language
English
LU publication?
yes
id
bf1743e5-0d63-4a9b-a276-f3d79881ad4c (old id 1141207)
date added to LUP
2008-08-13 12:00:50
date last changed
2016-10-13 04:27:48
@misc{bf1743e5-0d63-4a9b-a276-f3d79881ad4c,
  abstract     = {Due to its significant applicability for early detection, risk prediction and follow-up evaluation, prostate specific antigen (PSA) has revolutionized our ability to treat prostate cancer patients. With the prevalent use of PSA for early detection during the last two decades, disease characteristics have been altered towards early detected, localized tumors with a high chance of cure following local therapy. This advantage faces the risk of overdetection and overtreatment. In addition, PSA lacks both, sensitivity and specificity to accurately detect patients at risk of prostate cancer. Therefore, novel biomarkers are urgently needed to improve identification of men at risk of having the disease and to predict the natural behaviour of the tumor. Recent advances in the evaluation of high-throughput technologies have led to the discovery of novel candidate markers for prostate cancer. This article will briefly discuss current PSA-based strategies and review several novel biomarkers for prostate cancer, detectable in blood.},
  author       = {Steuber, Thomas and Helo, Pauliina and Lilja, Hans},
  issn         = {1433-8726},
  language     = {eng},
  number       = {2},
  pages        = {111--119},
  publisher    = {ARRAY(0x7987878)},
  series       = {World Journal of Urology},
  title        = {Circulating biomarkers for prostate cancer},
  url          = {http://dx.doi.org/10.1007/s00345-007-0160-0},
  volume       = {25},
  year         = {2007},
}